Amgen Inc.

Noven Therapeutics, LLC

Travis Houston

Stephan D Parent

David Alan Engers

Henry Morrison

Jason S Tedrow

Yonglai Yang

Courtney Johnson

Bruce Charles Friedman

Melanie Bevill

Disclosed herein are salt and solvate forms of. (1S,3'R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-methoxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.00]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (AMG 176): such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.

Salt forms and solvates of Mcl-1 antagonists

The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60&#xb0; C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient. Methods for the treatment using paroxetine mesylate in the form of a solid dispersion according to the invention are also disclosed.

Solid dispersions of amorphous paroxetine mesylate

Growing community of inventors

West Lafayette, IN, United States of America

Travis Houston